Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The mechanism by which mutations in the presenilin (PS) genes cause the most aggressive form of early-onset Alzheimer's disease (AD) is unknown, but fibroblasts from mutation carriers secrete increased levels of the amyloidogenic A beta 42 peptide, the main component of AD plaques. We established transfected cell and transgenic mouse models that coexpress human PS and amyloid beta-protein precursor (APP) genes and analyzed quantitatively the effects of PS expression on APP processing. In both models, expression of wild-type PS genes did not alter APP levels, alpha- and beta-secretase activity and A beta production. In the transfected cells, PS1 and PS2 mutations caused a highly significant increase in A beta 42 secretion in all mutant clones. Likewise, mutant but not wildtype PS1 transgenic mice showed significant overproduction of A beta 42 in the brain, and this effect was detectable as early as 2-4 months of age. Different PS mutations had differential effects on A beta generation. The extent of A beta 42 increase did not correlate with presenilin expression levels. Our data demonstrate that the presenilin mutations cause a dominant gain of function and may induce AD by enhancing A beta 42 production, thus promoting cerebral beta-amyloidosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies have shown that mice coexpressing FAD mutant APP and PS1 transgenes exhibit additive increases in A 𝛃 42 production (Borchelt et al., 1996, 1997; Citron et al., 1997; Holcomb et al., 1998), althoughrarely have more than two A 𝛃 42 -elevating FAD mutations been combined in transgenic animals.”
From Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation (2006) · cites this paper as Citron et al., 1997
In the citing paper
“each of these genetic forms of AD either selectively increases the extracellular concentration of A42 (Suzuki et al., 1994;Borchelt et al., 1996;Duff et al., 1996;Scheuner et al., 1996;Citron et al., 1997) or increases both A42 and A40 (Cai et al., 1993;Citron et al., 1994;Scheuner et al., 1996).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Citron et al., 1997
In the citing paper
“familial EOAD mutations in PSEN1 and PSEN2 typically result in an increased production of longer and more aggregation-prone derivatives of APP such as Aβ1–42 [47–49].”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [47]
Citations
Cites
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationScheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Self-citationRogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Self-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Self-citationEndoproteolysis of Presenilin 1 and Accumulation of Processed Derivatives In Vivo
Thinakaran, G., Borchelt, D. R., Lee, M. K., Slunt, H. H., Spitzer, L., Kim, G., Ratovitsky, T., Davenport, F., Nordstedt, C., Seeger, M., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80291-3 · Cited by 1,013
Self-citationPrusiner, S. B., Scott, M., Foster, D., Pan, K.-M., Groth, D., Mirenda, C., Torchia, M., Yang, S.-L., Serban, D., Carlson, G. A., et al. (1990) · Cell · doi:10.1016/0092-8674(90)90134-z · Cited by 871
Self-citationAmyloid β-Protein and the Genetics of Alzheimer's Disease
Selkoe, D. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.31.18295 · Cited by 799
Self-citationRadzicka, A., & Wolfenden, R. (1988) · Biochemistry · doi:10.1021/bi00405a042 · Cited by 606
Cited by
Items 901–1,000 of 1,002
Presenilin-1 Regulates the Expression of p62 to Govern p62-dependent Tau Degradation
Tung, Y.-T., Wang, B.-J., Hsu, W., Hu, M., Her, G. M., Huang, W., & Liao, Y. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8482-y · Cited by 14
Cavaleri, F. (2015) · Medical Hypotheses · doi:10.1016/j.mehy.2015.01.044 · Cited by 15
Ghate, P. S., Sidhar, H., Carlson, G. A., & Giri, R. K. (2014) · SpringerPlus · doi:10.1186/2193-1801-3-161 · Cited by 15
“Using these culture systems we observed the synthesis, secretion, oligomerization and aggregation of human beta amyloid peptides (A β 40 and A β 42) better than existing cellular models of AD and comparable to transgenic mouse models of AD (Citron et al. 1997; Oakley et al. 2006).”
Self-citationFukuchi, K., Li, L., Hart, M., & Lindsey, J. R. (2000) · International Journal of Experimental Pathology · doi:10.1046/j.1365-2613.2000.00156.x · Cited by 14
“Fax: (205) 975± 5519; E-mail: fukuchi@uab.edu increase production of highly amyloidogenic Ab consisting of 42 amino acids (Borchelt et al. 1996; Duff et al. 1996; Scheuner et al. 1996; Citron et al. 1997; Xia et al. 1997).”
BackgroundInterleukin-1α –889 C/T Polymorphism in Turkish Patients with Late-Onset Alzheimer’s Disease
Dursun, E., Gezen‐Ak, D., Ertan, T., Bılgıç, B., Gurvit, H. I., Emre, M., Eker, E., Engin, F., Uysal, Ö., & Yılmazer, S. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000193627 · Cited by 17
Identification of an antiamyloidogenic substance from mulberry leaves
Khaengkhan, P., Nishikaze, Y., Niidome, T., Kanaori, K., Tajima, K., Ichida, M., Harada, S., Sugimoto, H., & Kamei, K. (2009) · Neuroreport · doi:10.1097/wnr.0b013e32832fa645 · Cited by 14
Soluble amyloid β-protein is increased in frontotemporal dementia with tau gene mutations
Vitali, A., Piccini, A., Borghi, R., Fornaro, P., Siedlak, S. L., Smith, M. A., Gambetti, P. L., Ghetti, B. F., & Tabaton, M. (2004) · Journal of Alzheimer s Disease · doi:10.3233/jad-2004-6106 · Cited by 14
Uchihara, T., Sanjo, N., Nakamura, A., Han, K., Song, S., George‐Hyslop, P. S., & Fraser, P. E. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.12.011 · Cited by 16
Self-citationRiekkinen, P., Schmidt, B. H., & van der Staay, F. J. (1998) · Annals of Medicine · doi:10.3109/07853899809002606 · Cited by 15
Ounallah-Saad, H., Beeri, R., Goshen, I., Yirmiya, R., Renbaum, P., & Levy‐Lahad, E. (2009) · Gene · doi:10.1016/j.gene.2009.06.015 · Cited by 13
Acharya, N. K., Grossman, H. C., Clifford, P. M., Levin, E. C., Light, K., Choi, H.-N., Swanson, R. L., Kosciuk, M. C., Venkataraman, V., Libon, D. J., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231028 · Cited by 16
Proteomics Approach to Identify Biomarkers in Neurodegenerative Diseases
Nayak, A., Salt, G., Verma, S. K., & Kishore, U. (2015) · International review of neurobiology · doi:10.1016/bs.irn.2015.05.003 · Cited by 16
Janssen, L., Dubbelaar, M. L., Holtman, I. R., de Boer-Bergsma, J. J., Eggen, B. J. L., Boddeke, H. W. G. M., Deyn, P. P. D., & Dam, D. V. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.11.014 · Cited by 14
The Biochemistry of Alzheimer??s Disease
Stege, G. J. J., & Bosman, G. J. C. G. M. (1999) · Drugs & Aging · doi:10.2165/00002512-199914060-00004 · Cited by 14
The function of presenilin-1 in amyloid β-peptide generation and brain development
Säftig, P., Hartmann, D., & Strooper, B. D. (1999) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s004060050099 · Cited by 17
Fulopova, B., Stuart, K. E., Bennett, W. R., Bindoff, A. D., King, A. E., Vickers, J. C., & Canty, A. J. (2020) · The Journal of Comparative Neurology · doi:10.1002/cne.25060 · Cited by 13
“2021;529:1849–1862. wileyonlinelibrary.com/journal/cne © 2020 Wiley Periodicals LLC 1849 (PS1) genes (Citron et al., 1997; Garcia-Alloza et al., 2006; Hsiao et al., 1996; Jankowsky et al., 2004; Oakley et al., 2006).”
BackgroundShi, H., Sun, Y., Yao, Z., & Bai, M. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00487 · Cited by 12
Aurelian, S. M., Ciobanu, A. M., Carare, R. O., Stoica, S. I., Anghelescu, A., Ciobanu, V., Onose, G., Munteanu, C., Popescu, C., Andone, I., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216533 · Cited by 13
“Presenilin-1 (PS1) and presenilin-2 (PS2) span cellular membranes and are encoded on chromosomes 14 and 1, respectively [64].”
Tackling neurodegenerative diseases: animal models of Alzheimer’s disease and Parkinson’s disease
Raslan, A., & Kee, Y. (2013) · Genes & Genomics · doi:10.1007/s13258-013-0116-2 · Cited by 13
“Single transgenic PSEN1 or PSEN2 mice do not develop plaques (Borchelt et al. 1996; Citron et al. 1997), however the double transgenic lines Tg2576 and Tg(PSEN1-M146L) develop visible and extensive Ab plaque deposits in the hippocampus and cerebral cortex by 6–16 weeks of age (Holcomb et al.”
Villemagne, V. L., Ng, S., Cappai, R., Barnham, K. J., Fodero‐Tavoletti, M. T., Rowe, C. C., & Masters, C. L. (2006) · The Neuroradiology Journal · doi:10.1177/197140090601900406 · Cited by 12
Interstitial 1q25.3‐q31.3 deletion in a boy with mild manifestations
Höglund, P., Jalkanen, R., Marttinen, E. J., & Alitalo, T. (2003) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.20385 · Cited by 13
“The resulting increase in the production of neurotoxic forms of amyloid betapeptide favors deposition of amyloid plaques [Citron et al., 1997].”
BackgroundBACE1 Gene Expression and Protein Degradation
Zhou, W., Qing, H., Tong, Y., & Song, W. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1332.004 · Cited by 14
Monster plaques: What they tell us about Alzheimer's disease
Yankner, B. A. (1998) · Nature Medicine · doi:10.1038/nm0498-394 · Cited by 12
Rosenberg, R. N. (1997) · JAMA · doi:10.1001/jama.1997.03550150086041 · Cited by 12
Cell Signaling Abnormalities May Drive Neurodegeneration in Familial Alzheimer Disease
Robakis, N. K. R. K. (2013) · Neurochemical Research · doi:10.1007/s11064-013-1003-6 · Cited by 12
“Although early reports suggested that FAD mutations increase production of neurotoxic Ab42 by causing a gain of c-secretase function, the activity involved in its production [9, 12, 40], recent work [8, 43] showed that many PS1 FAD mutants do not increase Ab.”
BackgroundProteomics in Traditional Chinese Medicine with an Emphasis on Alzheimer’s Disease
Sulistio, Y. A., & Heese, K. (2015) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2015/393510 · Cited by 11
Establishment of experimental models for Alzheimer's disease research
Li, Y. (2013) · International Journal of Neuroscience · doi:10.3109/00207454.2013.804821 · Cited by 11
“In vitro studies show that mutated PSEN-1 gene results in higher production of Aβ [48].”
BackgroundAge-Related Progressive Synaptic Dysfunction: The Critical Role of Presenilin 1
Auffret, A., Mariani, J., & Rovira, C. (2010) · Reviews in the Neurosciences · doi:10.1515/revneuro.2010.21.4.239 · Cited by 11
Dutta, M., & Mattaparthi, V. S. K. (2017) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2017.1296783 · Cited by 11
“Moreover, the existing evidence indicates an increase in the ratio of Aβ42 to Aβ40 generation from the cleaved APP that correlates to the increase in toxicity both in vitro and in vivo (Citron et al., 1997; Dahlgren et al., 2002; Duff et al., 1996; Hellström-Lindahl, Viitanen, & Marutle, 2009; Kuperstein et al., 2010;…”
BackgroundExpression of Presenilin 1 mRNA in Rat Peripheral Organs and Brain
Nilsberth, C., Luthman, J., Lannfelt, L., & Schultzberg, M. (1999) · The Histochemical Journal · doi:10.1023/a:1003887922777 · Cited by 11
“Thus, increased levels of Aβ 1–42 have been observed in cell cultures transfected with mutated PS1 or PS2, in transgenic mice overexpressing mutated PS1, and in plasma from AD patients with PS1 or PS2 mutations (Duffet al. 1996, Scheuneret al. 1996, Citron et al.1997, Tomitaet al.1997).”
BackgroundNiidome, T., Goto, Y., Kato, M., Wang, P., Goh, S., Tanaka, N., Akaike, A., Kihara, T., & Sugimoto, H. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.06.130 · Cited by 11
The genetics of the amyloidoses: interactions with immunity and inflammation
Buxbaum, J. N. (2006) · Genes and Immunity · doi:10.1038/sj.gene.6364323 · Cited by 11
Janssen, L., Keppens, C., Deyn, P. P. D., & Dam, D. V. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.10.027 · Cited by 16
Synergistic Deleterious Effect of Chronic Stress and Sodium Azide in the Mouse Hippocampus
Delgado‐Cortés, M. J., Espinosa‐Oliva, A. M., Soto, M. S., Argüelles, S., Herrera, A. J., Mauriño, R., Villarán, R. F., Venero, J. L., Machado, A., & de Pablos, R. M. (2015) · Chemical Research in Toxicology · doi:10.1021/tx5004408 · Cited by 12
Studies of the Process of Amyloid Formation by Aβ Peptide
Galzitskaya, O. V., Galushko, E. I., & Selivanova, O. M. (2018) · Biochemistry (Moscow) · doi:10.1134/s0006297918140079 · Cited by 14
“Mutations of the presenilin 1 and presenilin 2 genes are accompanied by an increase in the level of Aβ(1 42) compared to Aβ(1 40), although the total amount of Aβ peptide formed remains constant [39].”
BackgroundMolecular pathology of Alzheimer's disease
Yamazaki, T., & Ihara, Y. (1997) · Neuropathology · doi:10.1111/j.1440-1789.1997.tb00051.x · Cited by 11
Li, Q., Cappai, R., Evin, G. M., Tanner, J. E., Gray, C. W., Beyreuther, K. T., & Masters, C. L. (1998) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/153331759801300504 · Cited by 11
Protease Inhibitors and their Involvement in Neurological Disorders
Tizón, B., & Levy, E. (2007) · Springer eBooks · doi:10.1007/978-0-387-30379-6_20 · Cited by 11
Gamliel, A., Teicher, C., Hartmann, T., Beyreuther, K. T., & Stein, R. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00830-8 · Cited by 14
Tomidokoro, Y., Ishiguro, K., Igeta, Y., Matsubara, E., Kanai, M., Shizuka, M., Kawarabayashi, T., Harigaya, Y., Kawakatsu, S., Ii, K., et al. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.0119 · Cited by 11
Ermekova, K. S., Chang, A., Zambrano, N., de Candia, P., Russo, T., & Sudol, M. (1998) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-4869-0_10 · Cited by 14
Shirotani, K., Takahashi, K., & Tabira, T. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00037-3 · Cited by 11
Erratum: Coexistence of superconductivity and ferromagnetism in the d-band metal ZrZn2
Pfleiderer, C., Uhlarz, M., Hayden, S. M., Vollmer, R., Löhneysen, H. V., Bernhoeft, N., & Lonzarich, G. G. (2001) · Nature · doi:10.1038/35088106 · Cited by 11
Cecchi, C., Evangelisti, E., Cascella, R., Zampagni, M., Benvenuti, S., Luciani, P., Deledda, C., Cellai, I., Wright, D., Saccardi, R., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110590 · Cited by 11
“The main protein component of these fibrillar deposits is a 40- or 42-amino-acid-long polypeptide, A (A 40 or A 42, respectively), a product of membrane amyloid- protein precursor (A PP) processing [1, 4–6].”
BackgroundNemirovsky, A., Shapiro, J., Baron, R., Kompaniets, A., & Monsonego, A. (2012) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2012.03.017 · Cited by 10
“…II alleles) to generate clearable plaques (Zota et al., 2009;Wang et al., 2011), it is presumably the PS1 L166Pmutation which drives the predominant formation of Aβ42 (Citron et al., 1997; Moehlmann et al., 2002; Radde et al., 2006) and hence the formation of vaccine resistant compact plaques.”
Chen, M., & Nguyen, H. T. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00329 · Cited by 10
“As the concept is so appealing, the β-/γ-secretases have been claimed to be “positively identified” and published in top-tier journals (Citron et al., 1997; Vassar et al., 1999), and thousands of studies have since followed.”
Kimura, N., Negishi, T., Ishii, Y., Kyuwa, S., & Yoshikawa, Y. (2004) · Neuroscience Research · doi:10.1016/j.neures.2004.03.010 · Cited by 10
Different Clinical Phenotypes in Siblings with a Presenilin-1 P264L Mutation
Ishizuka, T., Nakamura, M., Ichiba, M., Fujita, S., Takeuchi, K., Fujimoto, T., & Sano, A. (2012) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000338394 · Cited by 11
Disease‐modifying therapy for Alzheimer's disease: Challenges and hopes
Iwata, A., & Iwatsubo, T. (2013) · Neurology and Clinical Neuroscience · doi:10.1002/ncn3.20 · Cited by 10
Wang, X., Cui, J., Li, W., Zeng, X., Zhao, J., & Pei, G. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150313 · Cited by 10
“to the pathological generation of amyloid- (A ) in Alzheimer’s disease (AD) [3, 4].”
Consequence of Dementia and Cognitive Impairment by Primary Nucleation Pathway
Singh, A., Ansari, V. A., Ansari, T. M., Hasan, S. M., Ahsan, F., Singh, K., Wasim, R., Maheshwari, S., & Ahmad, A. (2023) · Hormone and Metabolic Research · doi:10.1055/a-2052-8462 · Cited by 10
Velez‐Pardo, C., Lopera, F. J., & Jiménez-Del-Río, M. (2000) · Journal of Alzheimer s Disease · doi:10.3233/jad-2000-2106 · Cited by 10
Pitsi, D., Kienlen‐Campard, P., & Octave, J. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01138.x · Cited by 10
“These mutations mainly result in an increase of the Ab1–42/Ab1–40 ratio (Borchelt et al. 1996; Citron et al. 1997).”
BackgroundCharacterization of APH-1 Mutants With a Disrupted Transmembrane GxxxG Motif
Araki, W., Saito, S., Takahashi‐Sasaki, N., Shiraishi, H., Komano, H., & Murayama, K. S. (2006) · Journal of Molecular Neuroscience · doi:10.1385/jmn:29:1:35 · Cited by 10
“Mutations in PS1 and PS2 associated with familial Alzheimer’s disease alter the specific location of the γ-site cleavage, increasing the level of Aβ42 relative to Aβ40 (Citron et al., 1997).”
BackgroundCell cycle and chromosome segregation defects in alzheimer's disease
Potter, H., Geller, L. N., Thomas, A. E., Conforto, D., & Chichkova, R. I. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)83340-0 · Cited by 10
Tanimukai, H., Sato, K., Kudo, T., Kashiwagi, Y., Tohyama, M., & Takeda, M. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00438-2 · Cited by 10
What do we learn from a few familial Alzheimer’s disease cases?
Haass, C., & Baumeister, R. (1998) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-7508-8_13 · Cited by 11
Genetic markers in the diagnosis of Alzheimer's disease
Rogaeva, E. A., Tandon, A., & George‐Hyslop, P. S. (2001) · Journal of Alzheimer s Disease · doi:10.3233/jad-2001-3304 · Cited by 13
“pathogenic presenilin mutations increase the production of Aβ42−43 peptides by altering the γ-secretase cleavage [10,21,34,115].”
Kölsch, H., Lütjohann, D., Jessen, F., Urbach, H., von Bergmann, K., Maier, W., & Heun, R. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-005-0319-z · Cited by 12
“Mutations in the genes encoding the b-amyloid precursor protein (APP) and the presenilins 1 and 2 are risk factors of earlyonset AD (Citron et al., 1997; Goate, 1998).”
Presenilin 1 Cleavage is a Universal Event in Human Organs
Okochi, M., Sahara, N., Kametani, F., Usami, M., Arai, T., Tanaka, K., Ishii, K., Yamamoto, A., & Mori, H. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00045-1 · Cited by 12
Animal Models in Biomedical Research
Quimby, F. W. (2002) · Elsevier eBooks · doi:10.1016/b978-012263951-7/50033-8 · Cited by 12
Presenilin-1 C410Y Alzheimer Disease Plaques Contain Synaptic Proteins
Haleem, K., Lippa, C. F., Smith, T. W., Kowa, H., Wu, J., & Iwatsubo, T. (2007) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317506298051 · Cited by 9
“This gamma-secretase exerts a proteolytic influence on a variety of type 1 membrane proteins including APP and notch-1.(16-20) AD is characterized histologically by beta-amyloid (Aβ) deposition in the form of extracellular plaques and tau-positive intracellular neurofibrillary tangles.”
BackgroundGSNgene frameshift mutations in Alzheimer’s disease
Jiang, Y., Wan, M., Xiao, X., Lin, Z., Liu, X., Zhou, Y., Liao, X., Lin, J., Zhou, H., Zhou, L., et al. (2023) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-330465 · Cited by 9
Biomarker identification in neurologic diseases: improving diagnostics and therapeutics
Coon, K. D., Dunckley, T. L., & Stephan, D. A. (2004) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.4.3.361 · Cited by 9
Sato, N., Okochi, M., Taniyama, Y., Kurinami, H., Shimamura, M., Takeuchi, D., Hamada, H., Fukumori, A., Kiyosue, K., Taguchi, T., et al. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.12.010 · Cited by 9
“Ah deposited in senile plaques is considered to be primarily involved in the pathogenesis of AD, because (1) familial AD (FAD) has been linked to mutations in the amyloid precursor protein (APP) (Goate et al., 1991; Mullan et al., 1992; Yoshioka et al., 1991), and (2) FAD-linked mutations in the amyloid precursor prot…”
BackgroundThe Pathophysiology of Alzheimer’s Disease
Selkoe, D. J. (2000) · Humana Press eBooks · doi:10.1007/978-1-59259-005-6_4 · Cited by 16
Self-citationMutation of conserved aspartates affect maturation of presenilin 1 and presenilin 2 complexes
Yu, G., Chen, F., Nishimura, M., Steiner, H., Tandon, A., Kawarai, T., Arawaka, S., Supala, A., Song, Y., Rogaeva, E. A., et al. (2000) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.2000.00301.x · Cited by 9
“Expression of PS1, PS2, or one of their mutants was investigated by standard Western blots as described (16, 24, 28).”
MethodSelf-citationβ-Amyloid peptide as a target for treatment of Alzheimer’s disease
Conde, S. (2002) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.12.4.503 · Cited by 9
“Overexpression of wild type PS genes does not correlate with any overproduction of Aβ42 [19].”
BackgroundPresenilin-1 Gene Intronic Polymorphism and Late-onset Alzheimer's Disease
Dursun, E., Gezen‐Ak, D., Eker, E., Ertan, T., Engin, F., Hanagasi, H. A., Gurvit, H. I., Emre, M., & Yılmazer, S. (2008) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988708324941 · Cited by 9
Satoh, J., & Kuroda, Y. (2001) · Neuropathology · doi:10.1046/j.1440-1789.2001.00378.x · Cited by 9
“overproduction of the highly amyloidogenic peptide (Aß1–42) in vitro and in vivo.(7,8) Targeted disruption of the PS1 gene or a missense mutation of this gene at two conserved transmembrane aspartate residues inhibits Neuropathology 2001; 21, 115–122”
BackgroundShin, J., Koh, J., & Mook‐Jung, I. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00434-6 · Cited by 9
Recent advances in transgenic model development for Alzheimer's disease
Sommer, B. (1998) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.7.12.2017 · Cited by 10
Aβ43 levels determine the onset of pathological amyloid deposition
Tambini, M. D., Yin, T., Yesiltepe, M., Breuillaud, L., Zehntner, S. P., d'Abramo, C., Giliberto, L., & D'Adamio, L. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104868 · Cited by 8
Lu, Q., Chen, W.-Y., Zhu, Z., Chen, J., Xu, Y., Kaewpet, M., Rukachaisirikul, V., Chen, L., & Shen, X. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2012.74 · Cited by 10
Pope, C. A., Wilkins, H., Swerdlow, R. H., & Wolfe, M. S. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210366 · Cited by 9
“-secretase, a protease complex that produces A (cid:2) peptides of varying lengths [9], and FAD mutations in presenilins increase the critical ratio of A (cid:2) 42 to A (cid:2) 40 that determines aggregation [10, 11].”
The Role of Aβ and Tau Oligomers in the Pathogenesis of Alzheimer’s Disease
Bhaskar, K., & Lamb, B. T. (2011) · Springer eBooks · doi:10.1007/978-94-007-2774-8_5 · Cited by 10
The Genetics of Alzheimer's Disease
Brindle, N., & George‐Hyslop, P. S. (2003) · Humana Press eBooks · doi:10.1385/1-59259-195-7:23 · Cited by 8
“Similar increases in Αβ42 production results were obtained in transgenic mice overexpressing PS mutations (76).”
BackgroundCellular reprogramming: A new way to understand aging mechanisms
İlçe, B. Y., Cagin, U., & Yılmazer, A. (2018) · Wiley Interdisciplinary Reviews Developmental Biology · doi:10.1002/wdev.308 · Cited by 8
“About 4% of familial ALS is linked to the TDP-43 mutation (Citron et al., 1997; Israel et al., 2012).”
BackgroundKumari, R., Chaudhary, A., & Mani, A. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e05546 · Cited by 9
Targeting γ-secretase for familial Alzheimer’s disease
Wolfe, M. S. (2021) · Medicinal Chemistry Research · doi:10.1007/s00044-021-02744-3 · Cited by 8
Absence of tissue transglutaminase reduces amyloid‐beta pathology in APP23 mice
Wilhelmus, M. M. M., Chouchane, O., Loos, M., Jongenelen, C. A. M., Brevé, J. J. P., Jonker, A. J., Bol, J. G. J. M., Smit, A. B., & Drukarch, B. (2022) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12796 · Cited by 9
“In line with these observations, in AD mouse models, such as the APP/PS1 [45] and APP23 model, anti-TG2 antibody immunoreactivity is found in astrocytes associated with both parenchymal and vascular Aβ deposits [17].”
ResultKou, J., Kim, H. D., Jin, J., Cao, D., Li, L., Lalonde, R., & Fukuchi, K. (2010) · Brain Research · doi:10.1016/j.brainres.2010.07.102 · Cited by 9
“Overexpression of the mutant forms of these genes in transgenic mice led to the high levels of Aβ accumulation in the brain as well as AD-like pathologic and behavioral alterations (Citron et al., 1997; Holcomb et al., 1998; Games et al., 1995; Hsiao et al., 1996).”
BackgroundVöglein, J., Willem, M., Trambauer, J., Schönecker, S., Dieterich, M., Biskup, S., Giudici, C., Utz, K. S., Oberstein, T. J., Brendel, M., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.08.034 · Cited by 8
Overview of the Alzheimer's Disease Pathology and Potential Therapeutic Targets
Cuello, A. C. (2007) · Springer eBooks · doi:10.1007/978-0-387-71522-3_1 · Cited by 8
“Mutations in PS1 (such as PS1 M146L) lead to the elevation of Aβ 1–42(43), by an as yet unknown mechanism (Borchelt et al., 1996; Citron et al., 1997; Duff et al., 1996; Scheuner et al., 1996), which assumes a gain of function of the γ-secretase activity.”
BackgroundGeneration of Amyloid β Protein from a Presenilin-1 and βAPP Complex
Shizuka‐Ikeda, M., Matsubara, E., Ikeda, M., Kanai, M., Tomidokoro, Y., Ikeda, Y., Watanabe, M., Kawarabayashi, T., Harigaya, Y., Okamoto, K., et al. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6681 · Cited by 8
β‐Amyloid immunization approaches for Alzheimer's disease
Imbimbo, B. P. (2002) · Drug Development Research · doi:10.1002/ddr.10070 · Cited by 8
LeVine, H., & Walker, L. C. (2006) · Elsevier eBooks · doi:10.1016/b978-012369391-4/50012-6 · Cited by 12
Chen, M. (1998) · Frontiers in bioscience · doi:10.2741/a249 · Cited by 8
“both α- and γ-secretases); and (iii) current PS animal models, generated by means of "mutant gene insertion" (27,28), though overproducing Aß42/43, have remained cognitively healthy (29) [Ca levels are normal; and no excessive APP available; thus total Aß levels, tau dephosphorylation and degradation and neurotransmis…”
BackgroundImplications of presenilin 1 mutations in Alzheimer’s disease
Komano, H., Sudoh, S., Kawamura, Y., Wang, R., & Yanagisawa, K. (1999) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(98)00135-3 · Cited by 9
Koivisto, A. M. (2006) · Cited by 15
Metabolism of Presenilin 1: Influence of Presenilin 1 on Amyloid Precursor Protein Processing
Borchelt, D. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00026-8 · Cited by 8
Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C. A., Hardy, J., Duff, K., Jantzen, P. T., DiCarlo, G., Wilcock, D. M., et al. (2001) · Nature · doi:10.1038/35088102 · Cited by 8
Sun, Y., Shi, Y., Li, C., & Shi, H. (2024) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c02343 · Cited by 7
Li, Y., Wang, H., Wang, Y., Chen, Z., Liu, Y., Tian, W., Kang, X., Pashang, A., Kulasiri, D., Yang, X., et al. (2024) · MedComm · doi:10.1002/mco2.768 · Cited by 9
Genetic variants in PSEN2 and correlation to CSF β-amyloid42 levels in AD
Разумовна, Л. Е., Stingl, J., Thal, D. R., Ghebremedhin, E., Strauss, J., Özer, E., Bertram, L., von Einem, B., Tumani, H., Otto, M., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.07.017 · Cited by 7
“Presenilin mutations might cause FAD through a ain of a deleterious function that elevates the amount of xtraneuronal A 42 (Borchelt et al., 1996; Citron et al., 1997; Duff et al., 1996; Tomita et al., 1997; Xia et al., 1997).”
BackgroundThe roles of GxxxG motif and gamma-secretase components in APP processing
Kim, J. (2009) · Interdisciplinary Bio Central · doi:10.4051/ibc.2009.4.0015 · Cited by 2
Bell, S. M., Wareing, H., Hamshaw, A., De, S., New, E., Shaw, P. J., De Marco, M., Venneri, A., Blackburn, D. J., Ferraiuolo, L., et al. (2023) · doi:10.1101/2023.03.23.534020 · Cited by 1
Kordower (1999) · doi:10.1002/1531-8249(199909)46:3
Nakagawa (1999) · doi:10.1002/(sici)1096-9861(19990830)411:3
Metadata
- Authors
- Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-wood, K., Lee, M., Seubert, P., Davis, A., Kholodenko, D., Motter, R., Sherrington, R., Perry, B., Yao, H., Strome, R., Lieberburg, I., Rommens, J., Kim, S., Schenk, D., Fraser, P., St George Hyslop, P., & Selkoe, D. J.
- Affiliations
- Brigham and Women's Hospital (US)
- University of Toronto (CA)
- McLaughlin Research Institute (US)
- Harvard University (US)
- ORCID
- Venue
- Nature Medicine
- Published
- 1997-01
- Volume
- 3
- Issue
- 1
- Pages
- 67-72
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2081998222
- Cited by
- 1,271
- References
- 28
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 15 · 2023: 20 · 2022: 18 · 2021: 26 · 2020: 29 · 2019: 28 · 2018: 20 · 2017: 20 · 2016: 32 · 2015: 35 · 2014: 38 · 2013: 33 · 2012: 49
- FWCI
- 68.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (64309)
- National Institute on Aging (AG 12749, AG-06173, AG 106812, R01AG012749)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- presenilin mutations, Alzheimer's disease, amyloid-beta 42, presenilin 1, presenilin 2, gain-of-function mutations, transgenic mouse model, beta-amyloidosis, early-onset Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Animals, Brain, Cell Line, Enzyme-Linked Immunosorbent Assay, Genetic Vectors, Hippocampus, Humans, Membrane Proteins, Mice, Transgenic, Mutation, Peptide Fragments, Transfection, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Mice, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.